A feasibility study of bevacizumab plus dose-dense doxorubicin- cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer

Heather L. McArthur, Hope Rugo, Benjamin Nulsen, Laura Hawks, Jill Grothusen, Michelle Melisko, Mark Moasser, Matthew Paulson, Tiffany Traina, Sujata Patil, Qin Zhou, Richard Steingart, Chau Dang, Monica Morrow, Peter Cordeiro, Monica Fornier, John Park, Andrew Seidman, Diana Lake, Theresa GilewskiMaria Theodoulou, Shanu Modi, Gabriella D'Andrea, Nancy Sklarin, Mark Robson, Mary Ellen Moynahan, Steven Sugarman, Jane E. Sealey, John H. Laragh, Carmen Merali, Larry Norton, Clifford A. Hudis, Maura N. Dickler

Research output: Contribution to journal › Article › peer-review

25 Scopus citations

Sort by
Weight
Alphabetically

A feasibility study of bevacizumab plus dose-dense doxorubicin- cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer

Fingerprint

Medicine & Life Sciences